Get started
Author

Alexandra N. Eurell

Observed name: Alexandra Eurell
Observed institution: Dana-Farber Cancer Institute
OpenAlex ID: A5093398569
A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
2024 · Jorge J. Castillo, Shayna R Sarosiek, et al. · Blood · 9
PDF
A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia
2024 · Jorge J. Castillo, Steven P. Treon, et al. · Blood · 7
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study
2025 · Jorge Castillo, Gottfried von Keudell, et al. · Blood · 5
Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.
2025 · Shayna Sarosiek, Mary Kwok, et al. · Blood · 3
PDF
Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2023 · Jorge J. Castillo, Shayna R Sarosiek, et al. · Blood · 3
Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications
2025 · Alberto Guijosa, Nickolas Tsakmaklis, et al. · Blood · 2
PDF
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
2026 · Jorge J. Castillo, Andrew R. Branagan, et al. · American Journal of Hematology · 1
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
2026 · Alberto Guijosa, Nickolas Tsakamaklis, et al. · American Journal of Hematology · 1
Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia
2025 · Jorge Castillo, Andrew Branagan, et al. · Blood · 1
PDF
Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2024 · Jorge J. Castillo, Shayna R Sarosiek, et al. · Blood · 1
PDF
IBCL-884: Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-884 Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 12
Citation count: 33
H-index: 3
I10-index:
Year
Topic
Type